Total
0
Shares
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald
CEO, James Graham
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327
  • The ASX-lister announced it had registered R327 with the Australian and New Zealand Clinical Trial Registry for a phase I/II topical burns study
  • The study is set to test 30 patients over two weeks in a bid to test the efficacy of the drug
  • In a broader context, Recce said the application represents one of the final administration stages required before the trial can commence
  • Recce Pharmaceuticals is up 6.63 per cent following the announcement, trading at $1.26

Recce Pharmaceuticals (RCE) is close to commencing human clinical trials for its topical burns treatment, RECCE 327.

The company today announced the drug had been registered with the Australian and New Zealand Clinical Trial Registry (ANZCTR) for a phase I/II topical burns study in humans.

In a broader context, Recce said the registration represents one of the final administration stages required before the trial can commence.

The ANZCTR includes trials from the full spectrum of therapeutic areas of pharmaceuticals, surgical procedures, preventive measures, lifestyle, devices, treatment and rehabilitation strategies and complementary therapies.

The trial has been registered under 'Proof of Concept Study of RECCE 327 Topical
Antibiotic Therapy for Infected Burn Wounds in Adults' and will involve 30 patients to test the efficacy of RECCE 327.

Over the course of 14 days, 10 patients are set to receive R327 daily while the remaining 20 receive treatment three times per week.

Recce Pharmaceuticals is up 6.63 per cent following the announcement, trading at $1.26 at 3:42 pm AEST.

RCE by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.
Microequities Asset Management (ASX:MAM) posts 140pc boost to half-yearly profit

" Patrys (ASX:PAB) receives $600k R&D tax incentive refund

Patrys (PAB), through its wholly owned Nucleus Therapeutics subsidiary, has received a research and development (R&D) tax incentive refund of $626,780 for the